Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone

Denosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT. Denosumab has also been used pre-operatively to downstage tumours with large soft tissue extension...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Sarcoma Res
Autors principals: Gaston, Czar Louie, Grimer, Robert J., Parry, Michael, Stacchiotti, Silvia, Dei Tos, Angelo Paolo, Gelderblom, Hans, Ferrari, Stefano, Baldi, Giacomo G., Jones, Robin L., Chawla, Sant, Casali, Paolo, LeCesne, Axel, Blay, Jean-Yves, Dijkstra, Sander P. D., Thomas, David M., Rutkowski, Piotr
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5022265/
https://ncbi.nlm.nih.gov/pubmed/27651889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13569-016-0056-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars